Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (20) clinical trials

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy in men with high-risk localized prostate cancer (this trial will enroll men with at least high risk prostate cancer defined by NCCN Guidelines Version 2.2017 ...

Phase

0.0 miles

Learn More »

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

PRIMARY OBJECTIVES: I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. SECONDARY OBJECTIVES: I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate ...

Phase

2.73 miles

Learn More »

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease. Results of this study may be pooled with the results of a separate study being conducted in participants with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ...

Phase

7.06 miles

Learn More »

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

PRIMARY OBJECTIVES: I. Determine the negative repeat biopsy rate by site directed and systematic prostate biopsy after 90-days of apalutamide. SECONDARY OBJECTIVES: I. Determine the rate of exit at 2 years from active surveillance due to pathologic reclassification. II. Determine the overall rate of exit at 2 years from active ...

Phase

7.99 miles

Learn More »

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population. 150 biopsy-nave patients with an elevated PSA (2-10 ng/mL) will be enrolled in this study. Within 28 days of informed consent, patients will ...

Phase

7.99 miles

Learn More »

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

PRIMARY OBJECTIVES: I. To compare the proportion of metastatic prostate cancer patients with a prostate specific antigen (PSA) decline of >= 50% over 8 cycles of docetaxel with ascorbic acid (Arm A) versus docetaxel with placebo (Arm B). II. To compare the proportion of adverse events (fatigue, nausea, bone pain, ...

Phase

7.99 miles

Learn More »

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

PRIMARY OBJECTIVES: I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone. SECONDARY OBJECTIVES: ...

Phase

7.99 miles

Learn More »

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

PRIMARY OBJECTIVES: To evaluate the effect of administration of nivolumab and ipilimumab on the proportion of prostate-specific antigen (PSA) responses (> 50% PSA decline) in metastatic castration-resistant prostate cancer (mCRPC) patients with detectable ARV7 transcript in circulating tumor cells (CTCs). SECONDARY OBJECTIVES; To evaluate the safety and tolerability of ipilimumab ...

Phase

7.99 miles

Learn More »

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Enzalutamide is a second-generation androgen receptor signaling inhibitor that significantly prolongs survival in patients with metastatic castration-resistant prostate cancer who have received prior docetaxel chemotherapy 35,36. Enzalutamide has demonstrated activity in cells that overexpress the androgen receptor. Unlike previous androgen receptor blocker (ARB) agents, Enzalutamide does not display any agonist ...

Phase

7.99 miles

Learn More »

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

The metastatic capacity of prostate cancer (PCa) behaves along a spectrum of disease that contains an oligometastatic state where metastases are limited in number and location. The importance of local consolidation of all tumor deposits in oligometastatic disease to forestall further metastatic dissemination is now backed by small randomized studies. ...

Phase

7.99 miles

Learn More »